Dengue - Pipeline Review, Q1 2011

Global Markets Direct
March 29, 2011
46 Pages - SKU: GMD6210064
Dengue - Pipeline Review, Q1 2011


Global Markets Direct’s, 'Dengue - Pipeline Review, Q1 2011', provides an overview of the Dengue therapeutic pipeline. This report provides information on the therapeutic development for Dengue, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Dengue. 'Dengue - Pipeline Review, Q1 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

  • A snapshot of the global therapeutic scenario for Dengue.
  • A review of the Dengue products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Dengue pipeline on the basis of therapeutic class, route of administration and molecule type.
  • Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.
Reasons to buy
  • Identify and understand important and diverse types of therapeutics under development for Dengue.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Dengue pipeline depth and focus of Dengue therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

More Dengue reports by Global Markets Direct

Dengue - Pipeline Review, H1 2015 by Global Markets Direct
Dengue - Pipeline Review, H1 2015SummaryGlobal Markets Direct’s, ‘Dengue - Pipeline Review, H1 2015’, provides an overview of the Dengue’s therapeutic pipeline.This report provides comprehensive ...
See all reports like this >>



    Online Download  USD 500  
    Global Site License  USD 1,500  
US: 800.298.5699
Int'l: +1.240.747.3093

Share this report

    Other tasks

    Join Alert Me now!
    Receive bi-weekly email alerts on new market research

    Sign up today!